JP2022514271A5 - - Google Patents
Info
- Publication number
- JP2022514271A5 JP2022514271A5 JP2021534702A JP2021534702A JP2022514271A5 JP 2022514271 A5 JP2022514271 A5 JP 2022514271A5 JP 2021534702 A JP2021534702 A JP 2021534702A JP 2021534702 A JP2021534702 A JP 2021534702A JP 2022514271 A5 JP2022514271 A5 JP 2022514271A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- raav
- nucleic acid
- composition according
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781380P | 2018-12-18 | 2018-12-18 | |
| US62/781,380 | 2018-12-18 | ||
| PCT/US2019/067247 WO2020132115A1 (en) | 2018-12-18 | 2019-12-18 | Methods and compositions for treating glycogen storage diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514271A JP2022514271A (ja) | 2022-02-10 |
| JP2022514271A5 true JP2022514271A5 (enExample) | 2022-05-20 |
| JP7486274B2 JP7486274B2 (ja) | 2024-05-17 |
Family
ID=69400618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534702A Active JP7486274B2 (ja) | 2018-12-18 | 2019-12-18 | 糖原病を処置するための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220017922A1 (enExample) |
| EP (1) | EP3898981B1 (enExample) |
| JP (1) | JP7486274B2 (enExample) |
| KR (1) | KR20210105390A (enExample) |
| CN (1) | CN113454226B (enExample) |
| AU (1) | AU2019405758B2 (enExample) |
| BR (1) | BR112021012104A2 (enExample) |
| CA (1) | CA3123841A1 (enExample) |
| DK (1) | DK3898981T5 (enExample) |
| ES (1) | ES2969222T3 (enExample) |
| IL (1) | IL283956A (enExample) |
| MX (1) | MX2021007379A (enExample) |
| PL (1) | PL3898981T3 (enExample) |
| PT (1) | PT3898981T (enExample) |
| WO (1) | WO2020132115A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023069891A1 (en) * | 2021-10-19 | 2023-04-27 | University Of Connecticut | Compositions and methods for the treatment of glycogen storage disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| JP2002191363A (ja) * | 1999-07-29 | 2002-07-09 | Herikkusu Kenkyusho:Kk | 全長ｃＤＮＡ合成用プライマー、およびその用途 |
| US7261544B2 (en) | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| ES2751999T3 (es) | 2008-01-29 | 2020-04-02 | Applied Genetic Tech Corporation | Producción recombinante de virus adeno-asociados usando células BHK en suspensión |
| WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
| WO2011094198A1 (en) | 2010-01-28 | 2011-08-04 | The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| WO2014127196A1 (en) * | 2013-02-15 | 2014-08-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Aav8 retinoschisin expression vector for treating x-linked retinoschisis |
| AU2014354839B2 (en) * | 2013-11-26 | 2020-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adeno-associated virus vectors for treatment of glycogen storage disease |
| WO2016106303A1 (en) * | 2014-12-23 | 2016-06-30 | THE UNITED STATES OF AMERICA, as representd by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Adeno-associated virus vectors encoding modified g6pc and uses thereof |
| FI3436593T3 (fi) | 2016-03-28 | 2023-03-16 | Ultragenyx Pharmaceutical Inc | Adenoviruksen lämpöinaktivointimenetelmiä |
| CA3050917A1 (en) * | 2017-01-30 | 2018-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant virus vectors for the treatment of glycogen storage disease |
-
2019
- 2019-12-18 BR BR112021012104-8A patent/BR112021012104A2/pt unknown
- 2019-12-18 US US17/311,869 patent/US20220017922A1/en active Pending
- 2019-12-18 PL PL19845789.7T patent/PL3898981T3/pl unknown
- 2019-12-18 ES ES19845789T patent/ES2969222T3/es active Active
- 2019-12-18 KR KR1020217022096A patent/KR20210105390A/ko active Pending
- 2019-12-18 MX MX2021007379A patent/MX2021007379A/es unknown
- 2019-12-18 WO PCT/US2019/067247 patent/WO2020132115A1/en not_active Ceased
- 2019-12-18 EP EP19845789.7A patent/EP3898981B1/en active Active
- 2019-12-18 CN CN201980083410.8A patent/CN113454226B/zh active Active
- 2019-12-18 AU AU2019405758A patent/AU2019405758B2/en active Active
- 2019-12-18 CA CA3123841A patent/CA3123841A1/en active Pending
- 2019-12-18 DK DK19845789.7T patent/DK3898981T5/da active
- 2019-12-18 PT PT198457897T patent/PT3898981T/pt unknown
- 2019-12-18 JP JP2021534702A patent/JP7486274B2/ja active Active
-
2021
- 2021-06-13 IL IL283956A patent/IL283956A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| JP2022500066A5 (enExample) | ||
| ES2640586T3 (es) | Secuencias del factor VIII | |
| JP7417303B2 (ja) | 血管性浮腫の治療としてのｃ１ｅｉのアデノ随伴ウイルス介在性送達 | |
| JP2021531752A5 (enExample) | ||
| JP2021533805A5 (enExample) | ||
| JP2024523707A5 (enExample) | ||
| TW201706412A (zh) | Ｆａｂｒｙ氏病基因療法 | |
| JP2022520232A5 (enExample) | ||
| JP2023515072A5 (enExample) | ||
| JP2023534037A5 (enExample) | ||
| JP7558535B2 (ja) | アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療 | |
| JP7702949B2 (ja) | ヒトｍｅｃｐ２遺伝子を発現するように設計されたトランスジーンカセット | |
| JP2019524090A5 (enExample) | ||
| JP2022516317A5 (enExample) | ||
| JP2024545183A5 (enExample) | ||
| JP2022551739A5 (enExample) | ||
| JP2024545186A5 (enExample) | ||
| FI3850089T3 (fi) | Polynukleotidejä | |
| JP2024546103A5 (enExample) | ||
| JP2024119900A (ja) | 優性遺伝性カテコラミン誘発多形性心室頻拍の治療のための組成物および方法 | |
| JP2022514271A5 (enExample) | ||
| WO2023202469A1 (zh) | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途 | |
| JP2024527742A5 (enExample) |